Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Compassionate use study of caspofungin in children with proven or suspected invasive mycosis or persistent febrile neutropenia.

Madero L, Sanchez de Toledo J, Castel V, Sevilla J, Gonzalez-Esteban J, Sanz-Rodriguez C.

J Chemother. 2009 Apr;21(2):229-31. No abstract available.

PMID:
19423481
2.

A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.

Yilmaz D, Balkan C, Ay Y, Akin M, Karapinar B, Kavakli K.

Mycoses. 2011 May;54(3):234-42. doi: 10.1111/j.1439-0507.2009.01808.x.

PMID:
19906090
3.

Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.

Cesaro S, Toffolutti T, Messina C, Calore E, Alaggio R, Cusinato R, Pillon M, Zanesco L.

Eur J Haematol. 2004 Jul;73(1):50-5.

PMID:
15182338
4.

Modern antifungal therapy for neutropenic fever.

Corey M.

Curr Hematol Malig Rep. 2006 Jun;1(2):95-100. doi: 10.1007/s11899-006-0029-0. Review.

PMID:
20425338
5.

Caspofungin versus liposomal amphotericin B for empirical therapy.

Marty FM, Lowry CM.

N Engl J Med. 2005 Jan 27;352(4):410-4; author reply 410-4. No abstract available.

PMID:
15675093
6.

A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.

Maertens JA, Madero L, Reilly AF, Lehrnbecher T, Groll AH, Jafri HS, Green M, Nania JJ, Bourque MR, Wise BA, Strohmaier KM, Taylor AF, Kartsonis NA, Chow JW, Arndt CA, DePauw BE, Walsh TJ; Caspofungin Pediatric Study Group.

Pediatr Infect Dis J. 2010 May;29(5):415-20. doi: 10.1097/INF.0b013e3181da2171.

PMID:
20431381
7.

Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study.

Tan BH, Low JG, Chlebicka NL, Kurup A, Cheah FK, Lin RT, Goh YT, Wong GC.

Int J Infect Dis. 2011 May;15(5):e350-6. doi: 10.1016/j.ijid.2011.01.011. Epub 2011 Mar 11.

8.

Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia.

Torres A, Serrano J, Rojas R, Martín V, Martín C, Tabares S, Molina JR, Capote M, Martínez F, Gómez P, Sánchez-García J.

Eur J Haematol. 2010 Mar;84(3):271-3. doi: 10.1111/j.1600-0609.2009.01367.x. Epub 2009 Oct 29. No abstract available.

PMID:
19878274
9.
10.

New antifungal drugs and the pediatric cancer patient: current status of clinical development.

Groll AH, Lehrnbecher T.

Klin Padiatr. 2005 May-Jun;217(3):158-68. Review.

PMID:
15858708
11.

Caspofungin therapy in immunocompromised children and neonates.

Somer A, Törün SH, Salman N.

Expert Rev Anti Infect Ther. 2011 Mar;9(3):347-55. doi: 10.1586/eri.11.4. Review.

PMID:
21417874
12.

Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children.

Koo A, Sung L, Allen U, Naqvi A, Drynan-Arsenault J, Dekker A, Maloney AM, Dupuis LL.

Pediatr Infect Dis J. 2007 Sep;26(9):854-6.

PMID:
17721388
13.

Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.

Raad II, Zakhem AE, Helou GE, Jiang Y, Kontoyiannis DP, Hachem R.

Int J Antimicrob Agents. 2015 Mar;45(3):283-8. doi: 10.1016/j.ijantimicag.2014.08.012. Epub 2014 Oct 12.

PMID:
25455847
14.
15.

Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant.

Castagnola E, Machetti M, Cappelli B, Molinari AC, Morreale G, Dodero P, Tomà P, Faraci M.

Clin Microbiol Infect. 2004 Mar;10(3):255-7.

16.

[Outcome analysis of caspofungin in combination with voriconazole for treatment of 12 hematologic malignancies cases with invasive fungal infection].

Sun HL, Zhou X, Shen YF.

Zhonghua Xue Ye Xue Za Zhi. 2011 Aug;32(8):558-9. Chinese. No abstract available.

PMID:
22338183
17.

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE.

N Engl J Med. 2004 Sep 30;351(14):1391-402.

18.

Efficacy and safety of caspofungin therapy in children with invasive fungal infections.

Merlin E, Galambrun C, Ribaud P, Blanc T, Michel G, Auvrignon A, Stéphan JL.

Pediatr Infect Dis J. 2006 Dec;25(12):1186-8.

PMID:
17133169
19.

Caspofungin versus liposomal amphotericin B for empirical therapy.

Danaher PJ.

N Engl J Med. 2005 Jan 27;352(4):410-4; author reply 410-4. No abstract available.

PMID:
15675092
20.

Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.

Kubiak DW, Bryar JM, McDonnell AM, Delgado-Flores JO, Mui E, Baden LR, Marty FM.

Clin Ther. 2010 Apr;32(4):637-48. doi: 10.1016/j.clinthera.2010.04.005.

PMID:
20435233

Supplemental Content

Support Center